Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Plasma p-tau217 in Alzheimer's disease : Lumipulse and ALZpath SIMOA head-to-head comparison

Pilotto, Andrea ; Quaresima, Virginia ; Trasciatti, Chiara ; Tolassi, Chiara ; Bertoli, Diego ; Mordenti, Cristina ; Galli, Alice ; Rizzardi, Andrea ; Caratozzolo, Salvatore and Zancanaro, Andrea , et al. (2025) In Brain 148(2). p.408-415
Abstract

Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and single molecule array (SIMOA) AlZpath p-tau217. The study included 392 participants, 162 with Alzheimer's disease, 70 with other neurodegenerative diseases with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate Alzheimer's disease from other neurodegenerative diseases and controls was investigated using receiver operating characteristic analyses. The p-tau217... (More)

Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and single molecule array (SIMOA) AlZpath p-tau217. The study included 392 participants, 162 with Alzheimer's disease, 70 with other neurodegenerative diseases with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate Alzheimer's disease from other neurodegenerative diseases and controls was investigated using receiver operating characteristic analyses. The p-tau217 levels measured by the two techniques demonstrated a strong correlation, showing a consistent relationship with CSF p-tau181 levels. In head-to-head comparison, Lumipulse and SIMOA showed similar diagnostic accuracy for differentiating Alzheimer's disease from other neurodegenerative diseases [area under the curve (AUC) 0.952, 95% confidence interval (CI) 0.927-0.978 versus 0.955, 95% CI 0.928-0.982, respectively] and healthy controls (AUC 0.938, 95% CI 0.910-0.966 and 0.937, 95% CI 0.907-0.967 for both assays). This study demonstrated the high precision and diagnostic accuracy of p-tau217 for the clinical diagnosis of Alzheimer's disease using fully automated or semi-automated techniques.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, ALZPath, Lumipulse, p-tau217, plasma markers, SIMOA
in
Brain
volume
148
issue
2
pages
8 pages
publisher
Oxford University Press
external identifiers
  • pmid:39679606
  • scopus:85217028880
ISSN
0006-8950
DOI
10.1093/brain/awae368
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2024 The Author(s). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
id
53617286-6d94-45e3-8bba-c84d3ecd9d6a
date added to LUP
2025-03-27 16:23:15
date last changed
2025-07-03 23:23:51
@article{53617286-6d94-45e3-8bba-c84d3ecd9d6a,
  abstract     = {{<p>Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and single molecule array (SIMOA) AlZpath p-tau217. The study included 392 participants, 162 with Alzheimer's disease, 70 with other neurodegenerative diseases with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate Alzheimer's disease from other neurodegenerative diseases and controls was investigated using receiver operating characteristic analyses. The p-tau217 levels measured by the two techniques demonstrated a strong correlation, showing a consistent relationship with CSF p-tau181 levels. In head-to-head comparison, Lumipulse and SIMOA showed similar diagnostic accuracy for differentiating Alzheimer's disease from other neurodegenerative diseases [area under the curve (AUC) 0.952, 95% confidence interval (CI) 0.927-0.978 versus 0.955, 95% CI 0.928-0.982, respectively] and healthy controls (AUC 0.938, 95% CI 0.910-0.966 and 0.937, 95% CI 0.907-0.967 for both assays). This study demonstrated the high precision and diagnostic accuracy of p-tau217 for the clinical diagnosis of Alzheimer's disease using fully automated or semi-automated techniques.</p>}},
  author       = {{Pilotto, Andrea and Quaresima, Virginia and Trasciatti, Chiara and Tolassi, Chiara and Bertoli, Diego and Mordenti, Cristina and Galli, Alice and Rizzardi, Andrea and Caratozzolo, Salvatore and Zancanaro, Andrea and Contador, José and Hansson, Oskar and Palmqvist, Sebastian and De Santis, Giovanni and Zetterberg, Henrik and Blennow, Kaj and Brugnoni, Duilio and Suárez-Calvet, Marc and Ashton, Nicholas J. and Padovani, Alessandro}},
  issn         = {{0006-8950}},
  keywords     = {{Alzheimer's disease; ALZPath; Lumipulse; p-tau217; plasma markers; SIMOA}},
  language     = {{eng}},
  month        = {{02}},
  number       = {{2}},
  pages        = {{408--415}},
  publisher    = {{Oxford University Press}},
  series       = {{Brain}},
  title        = {{Plasma p-tau217 in Alzheimer's disease : Lumipulse and ALZpath SIMOA head-to-head comparison}},
  url          = {{http://dx.doi.org/10.1093/brain/awae368}},
  doi          = {{10.1093/brain/awae368}},
  volume       = {{148}},
  year         = {{2025}},
}